BioCentury | May 18, 2015
Company News

Evolva Holding, Emergent BioSolutions deal

...Emergent acquired Evolva’s EV-035 antibiotic portfolio, including preclinical melioidosis candidate GC-072 . The U.S. Department of...
BioCentury | Sep 1, 2014
Company News

Evolva Holding, U.S. Department of Defense infectious news

...development for GC-072, a broad-spectrum antibiotic. GC-072 is the lead compound in Evolva’s EV-035 program. EV-035...
BioCentury | Sep 30, 2013
Company News

Evolva Holding infectious news

..."several months." The preclinical broad spectrum antibiotic is the lead compound in Evolva's EV-035 program. EV-035...
BioCentury | Sep 17, 2012
Clinical News

Evolva Holding preclinical data

...In a mouse model of melioidosis, analogs of EV-035 led to 21-day survival rates of 87.5%...
...vs. 12.5% for vehicle-treated controls. In mice challenged with methicillin-resistant Staphylococcus aureus (MRSA), analogs of EV-035...
...Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco. EV-035...
Items per page:
1 - 4 of 4